Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

NCT05259319 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer
Metastatic Bladder Cancer
Metastatic Renal Cell Carcinoma
Metastatic Head and Neck Cancer

Interventions

DRUG: Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]
DRUG: Tiragolumab
RADIATION: Stereotactic body radiation therapy (SBRT)

Sponsor

Centre Georges Francois Leclerc